AAFPRS President Addresses Concerns About Moderna COVID-19 Vaccine
AAFPRS will continue monitoring reports of incidents of reactions in patients with dermal fillers who received the Moderna COVID-19 vaccine.
AAFPRS will continue monitoring reports of incidents of reactions in patients with dermal fillers who received the Moderna COVID-19 vaccine.
Approval is based on Phase 3 data showing high rates of skin clearance in patients eligible for systemic treatment or phototherapy.